Advanced Search
Contact | Corporate | Help

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

Sponsors:
  • Dana-Farber Cancer Institute
  • Brigham and Women's Hospital
  • Massachusetts General Hospital
  • Beth Israel Deaconess Medical Center
  • Genentech
  • Sanofi-Synthelabo
Phases:
  • Phase II
IndicationsAcronym:
  • Colorectal Cancer
  • Neoplasm Metastasis
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: erlotinib
  • Drug: FOLFOX
  • Drug: bevacizumab
Enrollment:
35

Additional information about NCT00116506.


SourceSolution © 2008-2012